Home LiteratureArticle Details
PMID: 24048068 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Tumour heterogeneity in the clinic.

Nature ·Vol. 501 ·No. 7467 ·2013-09-19 ·Pages 355-64

Bedard PL, Hansen AR, Ratain MJ, Siu LL

Abstract

Recent therapeutic advances in oncology have been driven by the identification of tumour genotype variations between patients, called interpatient heterogeneity, that predict the response of patients to targeted treatments. Subpopulations of cancer cells with unique genomes in the same patient may exist across different geographical regions of a tumour or evolve over time, called intratumour heterogeneity. Sequencing technologies can be used to characterize intratumour heterogeneity at diagnosis, monitor clonal dynamics during treatment and identify the emergence of clinical resistance during disease progression. Genetic interpatient and intratumour heterogeneity can pose challenges for the design of clinical trials that use these data.

MeSH Terms
Clinical Trials as Topic/methods Clonal Evolution/genetics Gene Expression Profiling/methods Humans Longitudinal Studies/methods Neoplasm Metastasis/pathology Neoplasms/diagnosis,genetics,pathology,therapy Time Factors
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Bedard Philippe L
Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, Ontario, Canada.
Hansen Aaron R
Ratain Mark J
Siu Lillian L
References (102)
102 references, click to expand
  1. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.
    Nature. 2013 May 2;497(7447):108-12 PMID: 23563269
  2. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
    N Engl J Med. 2011 Jun 30;364(26):2507-16 PMID: 21639808
  3. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma.
    Histopathology. 2011 Nov;59(5):822-31 PMID: 22092393
  4. The patterns and dynamics of genomic instability in metastatic pancreatic cancer.
    Nature. 2010 Oct 28;467(7319):1109-13 PMID: 20981101
  5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
    N Engl J Med. 2009 Sep 3;361(10):947-57 PMID: 19692680
  6. Comparative genomic analysis of primary versus metastatic colorectal carcinomas.
    J Clin Oncol. 2012 Aug 20;30(24):2956-62 PMID: 22665543
  7. Assuring the quality of next-generation sequencing in clinical laboratory practice.
    Nat Biotechnol. 2012 Nov;30(11):1033-6 PMID: 23138292
  8. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing.
    Clin Cancer Res. 2013 Feb 1;19(3):691-8 PMID: 23243218
  9. Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
    N Engl J Med. 2004 Aug 19;351(8):781-91 PMID: 15317891
  10. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet. 2010 Aug 28;376(9742):687-97 PMID: 20728210
  11. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.
    J Thorac Oncol. 2009 Jul;4(7):809-15 PMID: 19487967
  12. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.
    J Clin Oncol. 2008 Sep 1;26(25):4217-9 PMID: 18757341
  13. Drug development: Raise standards for preclinical cancer research.
    Nature. 2012 Mar 28;483(7391):531-3 PMID: 22460880
  14. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.
    Ann Oncol. 2011 Dec;22(12):2616-2624 PMID: 22071650
  15. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
    J Clin Oncol. 2012 Jul 20;30(21):2601-8 PMID: 22711854
  16. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
    J Thorac Oncol. 2011 Aug;6(8):1359-66 PMID: 21587085
  17. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
    Nature. 2012 Mar 28;483(7391):603-7 PMID: 22460905
  18. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
    Clin Pharmacol Ther. 2009 Jul;86(1):97-100 PMID: 19440188
  19. Analysis of circulating tumor DNA to monitor metastatic breast cancer.
    N Engl J Med. 2013 Mar 28;368(13):1199-209 PMID: 23484797
  20. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.
    Ann Oncol. 2012 Oct;23(10):2656-2662 PMID: 22689179
  21. Clonal selection drives genetic divergence of metastatic medulloblastoma.
    Nature. 2012 Feb 15;482(7386):529-33 PMID: 22343890
  22. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    N Engl J Med. 2008 Oct 23;359(17):1757-65 PMID: 18946061
  23. Cell-free nucleic acids as biomarkers in cancer patients.
    Nat Rev Cancer. 2011 Jun;11(6):426-37 PMID: 21562580
  24. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
    J Clin Endocrinol Metab. 2008 Mar;93(3):682-7 PMID: 18073307
  25. Intratumor heterogeneity: evolution through space and time.
    Cancer Res. 2012 Oct 1;72(19):4875-82 PMID: 23002210
  26. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.
    Ann Oncol. 2009 Dec;20(12):1953-8 PMID: 19596702
  27. HER2 gene status in primary breast cancers and matched distant metastases.
    Breast Cancer Res. 2007;9(3):R31 PMID: 17511881
  28. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
    Nature. 2012 Jun 28;486(7404):537-40 PMID: 22722843
  29. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.
    Br J Cancer. 2011 Mar 15;104(6):1020-6 PMID: 21364579
  30. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing.
    Clin Chem. 2013 Jan;59(1):211-24 PMID: 23065472
  31. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.
    Br J Cancer. 2011 Apr 26;104(9):1372-6 PMID: 21487407
  32. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.
    Exp Mol Pathol. 2013 Aug;95(1):74-82 PMID: 23528430
  33. The genetic basis for cancer treatment decisions.
    Cell. 2012 Feb 3;148(3):409-20 PMID: 22304912
  34. Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases.
    Histopathology. 2013 Jan;62(2):305-14 PMID: 23020707
  35. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma.
    J Clin Oncol. 2012 Nov 10;30(32):3932-8 PMID: 22987085
  36. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
    N Engl J Med. 2012 Mar 8;366(10):883-892 PMID: 22397650
  37. Comparison and validation of genomic predictors for anticancer drug sensitivity.
    J Am Med Inform Assoc. 2013 Jul-Aug;20(4):597-602 PMID: 23355484
  38. HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations.
    Am J Clin Pathol. 2012 Apr;137(4):595-605 PMID: 22431536
  39. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?
    Per Med. 2011 Mar;8(2):161-173 PMID: 21695041
  40. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    J Clin Oncol. 2012 Jul 10;30(20):2522-9 PMID: 22614978
  41. Comprehensive molecular portraits of human breast tumours.
    Nature. 2012 Oct 4;490(7418):61-70 PMID: 23000897
  42. Genome remodelling in a basal-like breast cancer metastasis and xenograft.
    Nature. 2010 Apr 15;464(7291):999-1005 PMID: 20393555
  43. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma.
    Breast Cancer Res Treat. 2012 Jun;133(3):889-98 PMID: 22052326
  44. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
    J Clin Oncol. 2006 Oct 10;24(29):4764-74 PMID: 16954519
  45. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
    Clin Cancer Res. 2012 Nov 15;18(22):6373-83 PMID: 22966018
  46. Personalizing oncology: perspectives and prospects.
    J Clin Oncol. 2013 May 20;31(15):1904-11 PMID: 23589547
  47. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.
    Int J Cancer. 2013 Apr 1;132(7):1547-55 PMID: 22948899
  48. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.
    Cancer Sci. 2008 May;99(5):929-35 PMID: 18325048
  49. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
    Jpn J Clin Oncol. 2011 May;41(5):593-9 PMID: 21406492
  50. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
    Nat Med. 2012 Feb 12;18(3):382-4 PMID: 22327622
  51. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.
    J Clin Oncol. 2012 Feb 20;30(6):593-9 PMID: 22124109
  52. Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy.
    Cancer. 2011 Feb 15;117(4):705-13 PMID: 20939012
  53. Genome evolution during progression to breast cancer.
    Genome Res. 2013 Jul;23(7):1097-108 PMID: 23568837
  54. Clonal architecture of secondary acute myeloid leukemia.
    N Engl J Med. 2012 Mar 22;366(12):1090-8 PMID: 22417201
  55. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.
    Ann Oncol. 2013 May;24(5):1267-73 PMID: 23293113
  56. Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma.
    Cancer Res. 1995 Apr 1;55(7):1569-77 PMID: 7882367
  57. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.
    Mol Cancer Ther. 2012 Dec;11(12):2704-8 PMID: 22962325
  58. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm.
    Cell. 2012 Mar 2;148(5):873-85 PMID: 22385957
  59. Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA)--HCFA. Final rule with comment period.
    Fed Regist. 1992 Feb 28;57(40):7002-186 PMID: 10170937
  60. Genetic heterogeneity and cancer drug resistance.
    Lancet Oncol. 2012 Apr;13(4):e178-85 PMID: 22469128
  61. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma.
    Breast Cancer Res. 2012 Aug 03;14(4):R115 PMID: 22863309
  62. The clonal evolution of tumor cell populations.
    Science. 1976 Oct 1;194(4260):23-8 PMID: 959840
  63. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.
    Cancer Discov. 2012 Jan;2(1):82-93 PMID: 22585170
  64. Molecular prescreening to select patient population in early clinical trials.
    Nat Rev Clin Oncol. 2012 Apr 03;9(6):359-66 PMID: 22473105
  65. Designing transformative clinical trials in the cancer genome era.
    J Clin Oncol. 2013 May 20;31(15):1834-41 PMID: 23589555
  66. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.
    J Clin Oncol. 2012 Feb 20;30(6):587-92 PMID: 22124102
  67. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
    Nature. 2012 Jun 28;486(7404):532-6 PMID: 22722830
  68. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.
    Control Clin Trials. 2000 Aug;21(4):343-59 PMID: 10913809
  69. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
    Clin Cancer Res. 2005 Jun 1;11(11):4182-90 PMID: 15930355
  70. Tumour evolution inferred by single-cell sequencing.
    Nature. 2011 Apr 7;472(7341):90-4 PMID: 21399628
  71. The BATTLE trial: personalizing therapy for lung cancer.
    Cancer Discov. 2011 Jun;1(1):44-53 PMID: 22586319
  72. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Clin Cancer Res. 2009 Jul 15;15(14):4554-60 PMID: 19584155
  73. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.
    PLoS One. 2012;7(1):e29336 PMID: 22235286
  74. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials.
    Clin Cancer Res. 2012 Feb 1;18(3):638-44 PMID: 22298897
  75. The implications of clonal genome evolution for cancer medicine.
    N Engl J Med. 2013 Feb 28;368(9):842-51 PMID: 23445095
  76. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor.
    Cell. 2012 Mar 2;148(5):886-95 PMID: 22385958
  77. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).
    Breast Cancer Res. 2010;12(6):R92 PMID: 21059212
  78. The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
    Nature. 2012 Apr 04;486(7403):395-9 PMID: 22495314
  79. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.
    Lancet Oncol. 2010 Oct;11(10):992-1000 PMID: 20667780
  80. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
    Ann Oncol. 2008 Mar;19(3):508-15 PMID: 17998284
  81. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
    Eur Urol. 2013 May;63(5):920-6 PMID: 22981675
  82. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
    Br J Cancer. 2008 Sep 16;99(6):923-9 PMID: 19238633
  83. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing.
    Sci Transl Med. 2012 Nov 28;4(162):162ra154 PMID: 23197571
  84. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.
    Am J Pathol. 2012 Nov;181(5):1807-22 PMID: 23062488
  85. Systematic identification of genomic markers of drug sensitivity in cancer cells.
    Nature. 2012 Mar 28;483(7391):570-5 PMID: 22460902
  86. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.
    Clin Chem. 2013 Jan;59(1):252-60 PMID: 23136247
  87. Detection of mutations in EGFR in circulating lung-cancer cells.
    N Engl J Med. 2008 Jul 24;359(4):366-77 PMID: 18596266
  88. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data.
    Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12042-7 PMID: 21730188
  89. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    N Engl J Med. 2001 Mar 15;344(11):783-92 PMID: 11248153
  90. Cancer genomics: technology, discovery, and translation.
    J Clin Oncol. 2012 Feb 20;30(6):647-60 PMID: 22271477
  91. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma.
    J Thorac Oncol. 2008 May;3(5):527-9 PMID: 18449007
  92. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
    Sci Transl Med. 2013 Jan 9;5(167):167ra4 PMID: 23303603
  93. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
    N Engl J Med. 2012 Feb 9;366(6):520-9 PMID: 22149876
  94. Biological diversity in metastatic neoplasms: origins and implications.
    Science. 1982 Sep 10;217(4564):998-1003 PMID: 7112116
  95. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution.
    Nature. 2009 Oct 8;461(7265):809-13 PMID: 19812674
  96. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.
    Sci Transl Med. 2012 May 30;4(136):136ra68 PMID: 22649089
  97. N-of-1 trials in the medical literature: a systematic review.
    Med Care. 2011 Aug;49(8):761-8 PMID: 21478771
  98. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
    Nat Rev Neurol. 2010 Jan;6(1):39-51 PMID: 19997073
  99. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
    Mol Cancer Ther. 2012 Sep;11(9):2062-71 PMID: 22723336
  100. Distant metastasis occurs late during the genetic evolution of pancreatic cancer.
    Nature. 2010 Oct 28;467(7319):1114-7 PMID: 20981102
  101. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
    Lancet. 2011 Aug 27;378(9793):771-84 PMID: 21802721
  102. Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer.
    PLoS One. 2013;8(2):e54170 PMID: 23418425
Article Info
Journal
Nature
Abbr.
Nature
ISSN
1476-4687
DOI
10.1038/nature12627
Published
2013-09-19
Pages
355-64
Language
English
Region
England
NLM ID
0410462
PMCID
PMC5224525
Subset
IM
Grants
NIGMS NIH HHS · U01 GM061393 · United States
NCI NIH HHS · UM1 CA186644 · United States
NIGMS NIH HHS · U01 GM61393 · United States
External Links
PubMed source DOI: 10.1038/nature12627 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2